nach oben

Erschienen in:

01.01.2007 | Review

Mast cells in rheumatoid arthritis

Erschienen in: Clinical Rheumatology | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) is a chronic disease of joints that is characterized by inflammation, abnormal cellular and humoral immune responses, and synovial hyperplasia. Mast cells (MCs) are involved in several of these inflammatory and immune events. MC-derived mediators induce edema, destroy connective tissue, and are involved in lymphocyte chemotaxis and infiltration and in pathological fibrosis of RA joints. Moreover, MCs are involved in angiogenesis during RA, and their proteolytic activity results in cartilage destruction and bone remodeling. Lastly, MCs could be a target in the treatment of RA.

Galli SJ (1990) New insight into “the riddle of mast cells”: microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 62:5–33PubMed

Metcalfe DD, Baram D, Mekori YA (1997) Mast cells. Physiol Rev 77:1033–1079PubMed

Irani AM, Schechter NM, Craig SS, De Blois G, Schwartz LB (1986) Two types of human mast cells that have distinct neutral protease composition. Proc Natl Acad Sci USA 83:4464–4468PubMedCrossRef

Irani AM, Schwartz LB (1994) Human mast cell heterogeneity. Allergy Proc 15:303–308PubMedCrossRef

Ishizaka T, Ishizaka K (1984) Activation of mast cells for mediator release through IgE receptor. Prog Allergy 34:188–235PubMed

Mekori YA, Metcalfe DD (2000) Mast cells in the innate immunity. Immunol Rev 173:131–140PubMedCrossRef

Benoist C, Mathis D (2002) Mast cells in autoimmune disease. Nature 420:875–878PubMedCrossRef

Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, Kovanen P, Piliponsky AM, Kambe N, Vliagoftis H, Levi-Schaffer F, Metz M, Miyachi Y, Befus D, Forsythe P, Kitamura Y, Galli S (2003) What is the physiological function of mast cells? Exp Dermatol 12:886–910PubMedCrossRef

Crivellato E, Finato N, Isola M, Ribatti D, Beltrami CA (2003) Low mast cell density in the human duodenal mucosa from chronic inflammatory duodenal bowel disorders is associated with defective villous architecture. Eur J Clin Investig 33:601–610CrossRef

10.

Dvorak AM (1994) Ultrastructural analysis of human basophil and mast cell recovery after secretion. Semin Clin Immunol 8:5–16

11.

Godfrey HP, Ilardi C, Engber W, Graziano FM (1984) Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum 27:852–856PubMedCrossRef

12.

Bridges AJ, Malone DG, Jicinsky J, Chen M, Ory P, Engber W, Graziano FM (1991) Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum 34:1116–1124PubMedCrossRef

13.

Olsson N, Ulfgren AK, Nilsson G (2001) Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann Rheum Dis 60:187–193PubMedCrossRef

14.

Gotis-Graham I, Smith M, Parker A, McNeil HP (1998) Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann Rheum Dis 57:664–671PubMedCrossRef

15.

Castells MC, Friend DS, Bunnell CA, Hu X, Kraus M, Osteen RT, Austen KF (1996) The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 98:831–840PubMedCrossRef

16.

Schwartz LB (1994) Mast cells: function and contents. Curr Opin Immunol 6:91–97PubMedCrossRef

17.

Malone DH, Irani AM, Schwartz LB, Barrett KE, Metcalfe DD (1986) Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritis. Arthritis Rheum 29:956–963PubMedCrossRef

18.

Gruber BL, Marchese MJ, Kew RR (1994) Transforming growth factorβ1 mediates mast cell chemotaxis. J Immunol 152:5860–5867PubMed

19.

Hartmann K, Henz BM, Krüger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T (1997) C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863–2870PubMed

20.

Olsson N, Siegbahn A, Nilsson G (1999) Serum amyloid A induces mast cell chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway. Biochem Biophys Res Commun 254:143–146PubMedCrossRef

21.

Nilsson G, Metcalfe DD, Taub DD (2000) Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response. Immunology 99:314–319PubMedCrossRef

22.

Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB (2002) Mast cell: a cellular link between autoantibodies and inflammatory arthritis. Science 297:1689–1692PubMedCrossRef

23.

Huang M, Berry J, Kandere K, Lytinas M, Karalis K, Theoharides TC (2002) Mast cell deficient W/W(v) mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. Int J Immunopathol Pharmacol 15:249–254PubMed

24.

Mattheos S, Christodoulou S, Kempuraj D, Kempuraj B, Karalis K, Theoharides TC (2003) Mast cells and corticotropin-releasing hormone (CRH) are required for experimental inflammatory arthritis. FASEB J 17:C44

25.

Blue ML, Conrad P, Webb DL, Sarr T, Macaro M (1993) Interacting monocytes and synoviocytes induce adhesion molecules by a cytokine-regulated process, Lymphokine Cytokine Res 12:213–218PubMed

26.

Matsushima K, Oppenheim JJ (1989) Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine 1:2–13PubMedCrossRef

27.

Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C, Baeuerle PA (1996) Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 39:583–591PubMedCrossRef

28.

Yoffe JR, Taylor DJ, Wooley DE (1984) Mast cell products stimulate collagenase and prostaglandin E production by cultures of adherent rheumatoid synovial cells. Biochem Biophys Res Commun 122:270–276PubMedCrossRef

29.

Yoffe JR, Taylor DJ, Woolley DE (1985) Mast cell products and heparin stimulate the production of mononuclear-cell factor by cultured human monocyte-macrophages. Biochem J 230:83–88PubMed

30.

Ruschpler P, Lorenz P, Eichler W, Koczan D, Hanel C, Scholz R, Melzer C, Thiesen HJ, Stiehl P (2003) High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis. Arthritis Res Ther 5:R241–R252PubMedCrossRef

31.

Noli C, Miolo A (2001) The mast cells in wound healing. Vet Dermatol 12:303–313PubMedCrossRef

32.

Kiener HP, Hofbauer R, Tohidast-Akrad M, Walchshofer S, Redlich K, Bitzan P, Kapiotis S, Steiner G, Smolen JS, Valent P (2000) Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum 43:164–174

33.

Stevens RL, Somerville LL, Sewell D, Swafford JR, Caulfield JP, Levi-Schaffer F, Hubbard JR, Dayton ET (1992) Serosal mast cells maintain their viability and promote the metabolism of cartilage proteoglycans when cocultured with chondrocytes. Arthritis Rheum 35:325–335PubMedCrossRef

34.

Chowdhury MH, Hamada C, Dempster DW (1992) Effects of heparin on osteoclast activity. J Bone Miner Res 7:771–777PubMedCrossRef

35.

Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D (2006) Angiogenesis in rheumatoid arthritis. Histol Histopathol 21:557–566PubMed

36.

Hiromatsu Y, Toda S (2003) Mast Cells and angiogenesis. Microsc Res Tech 60:64–69PubMedCrossRef

37.

Nagashima M, Yoshino S, Ishiwata T, Asano G (1995) Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 22:1624–1630PubMed

38.

Yamada T, Sawatsubashi M, Yakushiji H, Itoh Y, Edakuni G, Mori M, Robert L, Miyazaki K (1998) Localization of vascular endothelial growth factor in synovial membrane mast cells: examination with “multi-labelling subtraction immunostaining”. Virchows Arch 433:567–570PubMedCrossRef

39.

Tetlow LC, Wooley DE (1995) Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis 54:896–903PubMedCrossRef

40.

Kakizoe E, Li SH, Kobayashi Y, Nishikori N, Dekio S, Okunishi H (1999) Increases in mast cells and chymase in fibroproliferative paws of collagen-induced arthritic mice. Inflamm Res 48:318–324PubMedCrossRef

41.

Lees M, Taylor DJ, Woolley DE (1994) Mast cell proteinases activate precursor forms of collagenase and stromelysin but not of gelatinases A and B. Eur J Biochem 223:171–177PubMedCrossRef

42.

Suzuki K, Lees M, Newlands GFJ, Nagase H, Woolley DE (1995) Activation of precursors for matrix metalloproteinases 1 (collagenase) and 3 (stromelysin) by rat mast cell proteinases I and II. Biochem J 305:301–306PubMed

43.

Bonassar LJ, Frank EH, Murray JC, Paguio CG, Moore VL, Lark MW, Sandy JD, Wu JJ, Evre DR, Grodzinsky AJ (1995) Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum 38:173–183PubMedCrossRef

44.

He S, Gaca MDA, Walls AF (2001) The activation of synovial mast cells: modulation of histamine release by tryptase and chymase and their inhibitors. Eur J Pharmacol 412:223–229PubMedCrossRef

Titel: Mast cells in rheumatoid arthritis
Publikationsdatum: 01.01.2007
Erschienen in: Clinical Rheumatology / Ausgabe 1/2007
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-006-0305-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2007

Spontaneous pneumomediastinum and dermatomyositis may be a not so rare association: report of a case and review of the literature

Two cases with pachydermoperiostosis and discussion of tamoxifen citrate treatment for arthralgia

Retroperitoneal fibrosis and c-ANCA positivity

The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms

Kikuchi–Fujimoto Disease: analysis of 244 cases